Torbay Pharmacy Manufacturing Unit appoints md

Dr Nick Frampton to run the unit

The UK’s South Devon Healthcare NHS Foundation Trust has appointed Dr Nick Frampton as managing director of the Torbay Pharmacy Manufacturing Unit (PMU), which produces licensed pharmaceuticals, pharmaceutical specials and medical devices.

Frampton joins the firm from Advanced Medical Solutions Group, where he was vice president of sales and marketing and contributed to a period of double-digit growth. He has formerly held quality, technical and commercial roles at West Pharmaceutical Services, Ernest Jackson and Banner Pharmacaps.

You may also like

Finance

NorthEdge invests in sterile injectable CMO to accelerate international growth

Private equity firm NorthEdge has invested in sterile injectable contract manufacturer and licence holder, Torbay Pharmaceuticals (Torbay), to support its next phase of international growth
Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Finance

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
Finance

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
Finance

Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships

Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research
Finance

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
Finance

Kimberley-Clark to acquire Tylenol maker Kenvue in landmark $40bn deal

The transaction brings together two iconic American companies to create a combined portfolio of complementary products, including 10 billion-dollar brands, that touch nearly half the global population through every stage of life
Subscribe now